Previously, signal transducer and activator of transcription 3 (STAT3) was also proposed a prognostic marker for predicting the responsiveness of patients with CTCL to HDACIs [45]. This evidence concerns the gene STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma.